Evocalcet
 | |
| Clinical data | |
|---|---|
| Trade names | Orkedia |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C24H26N2O2 |
| Molar mass | 374.484 g·mol−1 |
Evocalcet (trade name Orkedia) is a drug for the treatment of hyperparathyroidism.[1] It acts as a calcium-sensing receptor agonist.[2]
In 2018, it was approved in Japan for treatment of secondary hyperparathyroidism in patients on dialysis.[3]
References[edit]
- ^ Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, et al. (2018). "A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro". PLOS ONE. 13 (4): e0195316. Bibcode:2018PLoSO..1395316K. doi:10.1371/journal.pone.0195316. PMC 5882164. PMID 29614098.
- ^ Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, et al. (June 2018). "Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism". Bioorganic & Medicinal Chemistry Letters. 28 (11): 2055–2060. doi:10.1016/j.bmcl.2018.04.055. PMID 29724589.
- ^ "Kyowa Hakko Kirin Launches Orkedia Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan" (Press release). Kyowa Hakko Kirin. May 22, 2018.
 | This hormonal preparation article is a stub. You can help Wikipedia by expanding it. |